PENTETIC ACID
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 390.0 | -9.4 | 2 | 11 | 209.0 | 16 | 0.64 |
- CAS
- 67436
- UNII
- 7A314HQM0I
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 64 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT02175069 | 2013-12-01 | Magnetic Resonance Imaging of Interscalene Plexus Block | Phase 4 | Completed |
| NCT01956409 | 2012-09-01 | Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis | Phase 4 | Recruiting |
| NCT01211873 | 2010-09-01 | Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions | Phase 3 | Completed |
| NCT01050829 | 2010-01-01 | Gadobutrol Magnevist-controlled Body Study | Phase 3 | Completed |
| NCT00937391 | 2010-01-01 | Contrast-enhanced MRI in Children 2 Months to <2 Years | Phase 3 | Completed |
| NCT01260636 | 2009-09-01 | Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries | Phase 3 | Completed |
| NCT00744939 | 2008-11-01 | Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist | Phase 4 | Completed |
| NCT00481845 | 2008-01-01 | Phase II Anastrozole and ZD6474 in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer | Phase 2 | Terminated |
| NCT00486473 | 2007-07-01 | Multihance Versus Magnevist in Breast MRI | Phase 3 | Completed |
| NCT00408083 | 2006-12-01 | Crossover Study With MultiHance vs a Comparator for Peripheral MRA | Phase 3 | Completed |
| NCT00395863 | 2006-11-01 | Multihance at 3 Tesla in Brain Tumors | Phase 4 | Completed |
| NCT00395733 | 2006-10-01 | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients | Phase 3 | Completed |
| NCT00395460 | 2006-09-01 | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients | Phase 3 | Completed |
| NCT00310544 | 2006-03-01 | Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction | Phase 2 | Completed |
| NCT00373152 | 2005-03-01 | MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer | Phase 2 | Withdrawn |
| NCT00652418 | 2004-07-01 | Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography | Phase 2 | Completed |
| NCT00310596 | 2004-01-01 | Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects | Phase 1 | Completed |
| NCT00309075 | 2003-12-01 | Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries | Phase 3 | Completed |
| NCT00310557 | 2003-12-01 | Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries | Phase 3 | Completed |
| NCT00310609 | 2003-12-01 | Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches | Phase 3 | Completed |
| NCT00185276 | 2003-03-01 | Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries | Phase 3 | Completed |
| NCT00681551 | 2003-02-01 | Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis | Phase 3 | Completed |
| NCT00043017 | 2002-05-01 | Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer | Phase 2 | Completed |
| NCT00019604 | 1998-08-01 | Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer | Phase 2 | Terminated |
| NCT00019227 | 1996-10-01 | Monoclonal Antibody Therapy in Treating Patients With Leukemia | Phase 1/Phase 2 | Completed |